Evaxion hosts r&d day and unveils the broad potential of its ai-immunology™ platform

Copenhagen, denmark, march 19, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) ("evaxion" or the "company"), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today hosts a research & development (r&d) day focusing on its core ai-immunology™ platform. the event will be hosted at our facilities in hØrsholm, denmark, between 14.00 – 18.00 cet / 9.00 a.m. - 1.00 p.m. est and can be accessed remotely here.
EVAX Ratings Summary
EVAX Quant Ranking